From the Research
An elevated Mean Platelet Volume (MPV) is a laboratory marker that requires clinical context for interpretation and is not typically treated with medication solely for this finding. The management of elevated MPV focuses on addressing any identified underlying condition rather than treating the elevated MPV itself. Common causes of elevated MPV include inflammatory conditions, cardiovascular disease, diabetes, certain medications, or recovery from bone marrow suppression 1.
Clinical Significance of Elevated MPV
The clinical significance of elevated MPV varies widely depending on the overall health status and other laboratory findings. It has been associated with a variety of prothrombotic and proinflammatory diseases, including cardiovascular diseases, cerebral stroke, respiratory diseases, chronic renal failure, intestine diseases, rheumatoid diseases, diabetes, and various cancers 1.
Investigation and Management
If your MPV is elevated, your doctor will likely investigate underlying causes through additional blood tests, medical history review, and possibly other diagnostic procedures. While an isolated elevated MPV might not require immediate action, it's essential to follow up with your healthcare provider to determine if further evaluation is needed, especially if you have other concerning symptoms or risk factors for cardiovascular disease.
Use of Antiplatelet Drugs
The use of antiplatelet drugs, such as aspirin, clopidogrel, combined aspirin and dipyridamole, and cilostazol, has been shown to reduce MPV in acute non-cardioembolic ischemic stroke patients 2. However, the management of elevated MPV should be individualized and based on the underlying condition.
Recent Studies
A recent study published in 2022 found that anagrelide, an oral antiplatelet agent, is recommended as a second-line therapy for patients with high-risk essential thrombocythemia experiencing intolerance or refractoriness to first-line approach, such as hydroxyurea or pegylated interferon alpha-2a 3. However, the study also highlighted the importance of limiting the use of anagrelide to JAK2-mutated subgroup, reducing exposure time, and periodic monitoring for the presence of bone marrow fibrosis.
Recommendation
In patients with elevated MPV, the focus should be on investigating and managing the underlying condition rather than treating the elevated MPV itself. The use of antiplatelet drugs, such as clopidogrel, may be beneficial in reducing MPV in certain conditions, such as acute non-cardioembolic ischemic stroke 2. However, the management of elevated MPV should be individualized and based on the underlying condition, and patients should be closely monitored for any changes in their condition.